V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220015036 | 220015110 | null | 94.2 | Palliative (P) | 2013-04-03 | 2013-08-29 | BENDAMUSTINE + RITUXIMAB | N | N | 220001559 | VENETOCLAX |
| 220015037 | 220015110 | 1.7 | null | Disease modification (D) | 2016-01-31 | 2016-03-05 | VIDE | Y | null | 220001559 | MELPHALAN |
| 220015038 | 220009685 | 1.67 | 68.8 | Palliative (P) | 2017-09-30 | 2017-12-24 | DABRAFENIB + TRAMETINIB | N | N | 220002814 | UKALL2011 |
| 220015039 | 220009686 | null | 53.6 | Palliative (P) | 2016-09-06 | 2016-09-07 | LENALIDOMIDE | N | N | 220003896 | DAUNORUBICIN |
| 220015040 | 220009688 | 1.83 | 76 | null | 2015-08-06 | 2016-06-30 | LIPOSOMAL DOXORUBICIN | N | N | 220003896 | PEMBROLIZUMAB |
| 220015041 | 220009693 | 1.81 | 11.4 | Palliative (P) | 2017-02-24 | 2017-03-03 | BEP 3 day | N | N | 220004682 | TRASTUZUMAB |
| 220015042 | 220009693 | 1.77 | 89.9 | Palliative (P) | 2016-10-07 | 2016-10-30 | Capecitabine + Oxaliplatin 21day | N | N | 220004682 | CETUXIMAB |
| 220015043 | 220009694 | 1.58 | 84.8 | Curative (C) | 2017-07-08 | 2018-03-12 | PEMBROLIZUMAB | N | N | 220006910 | EOX |
| 220015044 | 220015116 | 1.96 | 79 | Curative (C) | 2018-07-22 | 2018-07-22 | IPILIMUMAB + NIVOLUMAB | 1 | N | 220006910 | CVP R |
| 220015045 | 220009695 | 1.75 | 91.6 | Curative (C) | null | 2015-07-02 | RAVVA TRIAL | N | N | 220009544 | PEMETREXED |
| 220015046 | 220009697 | 1.81 | 46.1 | Palliative (P) | 2017-12-30 | 2018-02-16 | PEMBROLIZUMAB | 01 | N | 220010163 | CAMELLIA TRIAL |
| 220015047 | 220015117 | 1.81 | 89.4 | Disease modification (D) | 2015-03-04 | 2015-03-18 | Cisplatin 7 day | N | N | 220011016 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220015048 | 220015118 | 1.65 | 60.6 | Palliative (P) | 2016-07-25 | 2016-07-25 | CAPECITABINE + TEMOZOLOMIDE | N | N | 220013190 | CAPECITABINE + OXALIPLATIN |
| 220015049 | 220009699 | 1.6 | 125 | Curative (C) | 2016-03-05 | 2016-03-06 | CARBOPLATIN + RT | N | N | 220013384 | ARSENIC TRIOXIDE + ATRA |
| 220015050 | 220009699 | null | 106.2 | Curative (C) | 2018-06-24 | 2018-06-27 | MERCAPTOPURINE + METHOTREXATE | 02 | N | 220013384 | CISPLATIN + FLUOROURACIL |
| 220015051 | 220015122 | 1.55 | 72.6 | Curative (C) | 2015-07-05 | 2015-08-02 | Clofarabine+Cytarabine+Idarubicin | N | N | 220014128 | ETOPOSIDE |
| 220015052 | 220009704 | null | null | Curative (C) | null | 2016-04-11 | Alemtuzumab+Busulfan+CyclophosphMUD | N | null | 220014290 | MIDAC |
| 220015053 | 220009705 | null | 21.25 | Disease modification (D) | 2014-11-29 | 2014-12-09 | Capecitabine | N | N | 220014919 | CAV |
| 220015054 | 220009706 | null | null | null | 2016-08-08 | 2016-08-08 | CHOP R - 21 days | N | null | 220015896 | LENALIDOMIDE |
| 220015055 | 220009706 | 1.65 | null | null | 2018-01-22 | 2018-01-22 | BORTEZOMIB + THALIDOMIDE | null | null | 220015896 | ETOPOSIDE |
| 220015056 | 220018243 | 1.74 | 78.4 | Curative (C) | 2017-09-30 | 2017-09-30 | Ipilimumab | N | N | 220016525 | LIPOSOMAL CYTARABINE |
| 220015057 | 220018243 | 1.79 | 52.8 | Palliative (P) | 2014-05-19 | 2014-07-05 | AML LI-1 Trial | N | N | 220016525 | GEMCITABINE |
| 220015058 | 220009707 | 1.7 | 43.85 | Disease modification (D) | 2015-04-21 | 2015-04-21 | FLUDARABINE | N | N | 220016746 | IGEV R |
| 220015059 | 220015124 | 1.65 | 84.6 | Curative (C) | null | 2016-08-24 | Lenalidomide 25mg (Cycle 1 to 25) | N | N | 220017143 | MERCAPTOPURINE + METHOTREXATE |
| 220015060 | 220018244 | 1.61 | 74.2 | Curative (C) | 2015-09-28 | 2016-12-01 | FCR | N | N | 220017507 | CAPECITABINE + OXALIPLATIN |
| 220015061 | 220009709 | 1.57 | 113.9 | Curative (C) | 2013-11-19 | 2013-12-02 | CISPLATIN + FLUOROURACIL | N | N | 220017673 | AFATINIB |
| 220015062 | 220009711 | null | 72.3 | Neo-adjuvant (N) | 2015-05-18 | 2015-05-18 | LENALIDOMIDE | N | N | 220018110 | IPILIMUMAB + NIVOLUMAB |
| 220015063 | 220009712 | null | null | null | 2017-07-15 | 2017-07-15 | LENALIDOMIDE | null | N | 220018242 | CYTARABINE + FLUDARABINE + IDARUBICIN |
| 220015064 | 220009719 | 1.55 | 89.6 | Curative (C) | 2016-05-24 | 2016-05-28 | CARBOPLATIN + VINORELBINE | N | N | 220018543 | CARBOPLATIN |
| 220015065 | 220009720 | 1.65 | 63.9 | Palliative (P) | 2018-06-07 | 2018-06-07 | CARBOPLATIN | null | N | 220018755 | ERIBULIN |
| 220015066 | 220009721 | 1.85 | 61.2 | Disease modification (D) | 2012-07-14 | 2018-01-06 | Cetuximab + FOLFIRI cycle1 | 02 | N | 220019679 | CISPLATIN + PEMETREXED |
| 220015067 | 220009722 | 1.76 | 57 | null | null | 2017-08-11 | EOX | 01 | N | 220020424 | VIDE |
| 220015068 | 220009724 | 1.7 | 70.8 | Curative (C) | 2018-02-20 | 2018-02-20 | Doxorubicin + Ifosfamide | 02 | N | 220020429 | MERCAPTOPURINE + METHOTREXATE |
| 220015069 | 220009725 | 1.81 | 95.4 | Curative (C) | 2013-06-14 | 2013-06-14 | Cladribine (subcut) 5 days | 02 | N | 220020796 | ETOPOSIDE |
| 220015071 | 220015129 | null | 67.3 | Palliative (P) | 2018-10-17 | 2018-10-30 | Ifosfamide | N | N | 220021062 | PAZOPANIB |
| 220015072 | 220009728 | 1.58 | 58 | Curative (C) | 2014-11-28 | 2015-01-13 | Busulfan Oral | N | N | 220021070 | GEMCITABINE |
| 220015073 | 220009730 | 1.66 | 0 | Palliative (P) | 2013-06-12 | 2013-06-21 | Cetuximab +Cisplatin + FU (Cycle 1) | Y | N | 220021070 | CISPLATIN + RT |
| 220015074 | 220009730 | 1.7 | 71 | Curative (C) | 2018-01-11 | 2018-01-21 | BUSULFAN | 01 | N | 220021070 | IPILIMUMAB |
| 220015075 | 220009732 | 1.73 | 60.6 | Curative (C) | 2015-06-14 | 2015-06-20 | Carboplatin + Liposomal Doxorubicin | 01 | N | 220021593 | FLA |
| 220015076 | 220009732 | 1.58 | 70.5 | Palliative (P) | 2015-12-05 | 2015-12-26 | DABRAFENIB + TRAMETINIB | 02 | N | 220021593 | ARSENIC TRIOXIDE + ATRA |
| 220015077 | 220009732 | 1.62 | 78.4 | Curative (C) | 2017-08-04 | 2017-09-20 | DOXORUBICIN | 2 | N | 220021593 | CAPECITABINE + CARBOPLATIN |
| 220015078 | 220015132 | 1.36 | null | Curative (C) | 2013-11-25 | 2014-02-18 | Bevacizumab 7.5mg/kg | 02 | N | 220021758 | ALEMTUZUMAB + CYCLO + FLUDARABINE |
| 220015079 | 220009736 | 1.69 | null | Curative (C) | 2016-01-09 | 2016-01-17 | DHAP | 99 | null | 220021845 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220015080 | 220009737 | null | null | Palliative (P) | 2019-09-16 | 2019-09-16 | Capecitabine + Oxaliplatin 21day | N | null | 220021899 | FLUDARABINE |
| 220015081 | 220009738 | 1.8 | 75 | Curative (C) | 2017-05-05 | 2017-05-05 | CLOFARABINE + DAUNORUBICIN | 02 | null | 220021916 | PEMBROLIZUMAB |
| 220015082 | 220015133 | 1.6 | 71 | Curative (C) | 2018-11-26 | 2018-12-17 | Ipilimumab | N | N | 220021916 | CAPECITABINE + OXALIPLATIN |
| 220015083 | 220009739 | 1.7 | 65 | Curative (C) | null | 2014-04-07 | EOX | 2 | N | 220022309 | CETUXIMAB + RT |
| 220015084 | 220009742 | 1.65 | 84.8 | Curative (C) | null | 2019-03-25 | Bendamustine+Rituximab(Sub Courses) | null | N | 220022614 | IPILIMUMAB |
| 220015085 | 220009742 | 1.8 | 85.5 | Curative (C) | 2016-02-11 | 2016-02-16 | Busulfan Oral | 02 | N | 220022614 | CYCLOPHOSPHAMIDE + FLUDARABINE + THIOTEPA |
| 220015086 | 220009742 | 1.63 | 66.5 | Palliative (P) | 2017-12-22 | 2017-12-24 | Liposomal Doxorubicin (Caelyx) | 2 | N | 220022614 | CLADRIBINE + CYTARABINE + DAUNORUBICIN |